Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years or more, suffering from acromegaly~* Treatment naïve or treated subject (whatever the previous treatments except Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. Requiring a treatment with Somatostatin analog (SSA)~* Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within the previous 12 weeks (post-surgery MRI for operated subjects)~* In whom the physician has already decided to initiate a treatment with Lanreotide 120mg as a monotherapy~Exclusion Criteria:~* Subject previously/currently treated with Lanreotide 120mg~* History of radiotherapy for acromegaly~* Subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression~* Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists~* Active neoplastic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).